Our studies in lung adenocarcinoma suggest that SGLT2 is expressed in the earliest stages of cancer development, and pre-malignant lesions are exquisitely sensitive to SGLT2is because they do not express glucose transporters of the GLUT family. The gene discussed is SLC2A1; the disease is lung adenocarcinoma.